SKIN (SkinHealth Systems Inc. Class A Common Stock) Stock Analysis - News

SkinHealth Systems Inc. Class A Common Stock (SKIN) is a publicly traded Consumer Defensive sector company. As of May 21, 2026, SKIN trades at $0.65 with a market cap of $78.49M and a P/E ratio of -13.92. SKIN moved +4.00% today. Year to date, SKIN is -51.95%; over the trailing twelve months it is -59.91%. Its 52-week range spans $0.55 to $2.69. Analyst consensus is neutral with an average price target of $1.63. Rallies surfaces SKIN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What changed in SKIN news today?

SkinHealth Systems Q1 Revenue Falls 6.7% to $64.9M; Adjusted EBITDA Rises 16%: SkinHealth Systems reported Q1 2026 net sales of $64.9 million, down 6.7% year-over-year, driven by declines in delivery system and consumables sales. Net loss narrowed to $6.6 million while adjusted EBITDA climbed to $8.5 million as operating expenses fell 24%.

SKIN Key Metrics

Key financial metrics for SKIN
MetricValue
Price$0.65
Market Cap$78.49M
P/E Ratio-13.92
EPS$-0.05
Dividend Yield0.00%
52-Week High$2.69
52-Week Low$0.55
Volume1
Avg Volume0
Revenue (TTM)$296.12M
Net Income$-6.05M
Gross Margin64.91%

Latest SKIN News

Recent SKIN Insider Trades

  • Gruber Desiree sold 14.66K (~$22.02K) on Nov 20, 2024.
  • SAUNDERS BRENT L bought 40.45K (~$43.69K) on Aug 12, 2024.

SKIN Analyst Consensus

5 analysts cover SKIN: 0 strong buy, 1 buy, 3 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $1.63.

Common questions about SKIN

What changed in SKIN news today?
SkinHealth Systems Q1 Revenue Falls 6.7% to $64.9M; Adjusted EBITDA Rises 16%: SkinHealth Systems reported Q1 2026 net sales of $64.9 million, down 6.7% year-over-year, driven by declines in delivery system and consumables sales. Net loss narrowed to $6.6 million while adjusted EBITDA climbed to $8.5 million as operating expenses fell 24%.
Does Rallies summarize SKIN news?
Yes. Rallies summarizes SKIN news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is SKIN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for SKIN. It does not provide personalized investment advice.
SKIN

SKIN